Alumis Inc. Common Stock (ALMS) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है South San Francisco, CA, United States. वर्तमान CEO हैं Martin Babler.
ALMS के पास है IPO तिथि 2021-02-22, 168 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Global Select, बाजार पूंजीकरण $2.82B.
Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for autoimmune and neuroinflammatory disorders. The company's lead candidate, ESK-001, is an allosteric tyrosine kinase 2 (TYK2) inhibitor in development for plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis. Additionally, Alumis is advancing A-005, a brain-penetrant TYK2 inhibitor designed to treat neuroinflammatory and neurodegenerative diseases. Founded in 2021 and formerly known as Esker Therapeutics, the company rebranded to Alumis Inc. in January 2022 and is headquartered in South San Francisco, California.
